Multiple myeloma has twice the incidence and death rate in Black people, compared with White people. Yet, Black people are half as likely to undergo a stem cell transplantation despite having similar, if not better, survival rates compared to White people, when given standard of care treatment. Chasms in early diagnosis, treatment options and access, survival rate, and more, remain for racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncology treatment for multiple myeloma, thus resulting in delayed diagnosis and suboptimal clinical management, prognosis, and survival rate.
In this CME Outfitters BriefCase, faculty experts will guide learners through a patient case scenario reflecting the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with multiple myeloma. This program will provide actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve multiple myeloma treatment.
At the end of this CME/CE activity, participants should be able to identify the impact of health inequities on patients with multiple myeloma and develop individual treatment strategies for optimal outcomes.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses/nurse navigators, pharmacists, and dieticians specializing in hematology, pathology, radiology, or primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Mikhael reports the following financial relationships:
Consultant: Amgen Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Karyopharm; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Usmani reports the following financial relationships:
Advisory Board: AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; EdoPharma; Genentech, Inc.; Gilead Sciences, Inc.; GSK; Janssen Pharmaceuticals, Inc.; Oncopeptides, Inc.; Sanofi; Seattle Genetics, Inc.; Secura Bio; SkylineDx USA, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teneobio, Inc.
Research Support: Amgen Inc.; Array BioPharma Inc.; Bristol Myers Squibb Company; Celgene Corporation; GSK; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pharmacyclics, Inc.; Sanofi; Seattle Genetics, Inc.; SkylineDx USA, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau: Amgen Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; and Sanofi
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.